Despite advances in treatment for metastatic prostate cancer, patients eventually progress to castrate-resistant disease and ultimately succumb to their cancer.
Androgen deprivation therapy (ADT) is the standard treatment for metastatic prostate cancer and has been shown to improve median time to progression and median survival time. Research suggests that castrate-resistant clones may be present early in the disease process prior to the initiation of ADT. These clones are not susceptible to ADT and may even flourish when androgen-responsive clones are depleted. Stereotactic body radiation therapy (SBRT) is a safe and efficacious method of treating clinically localized prostate cancer and metastases. In patients with a limited number of metastatic sites, SBRT may have a role in eliminating castrate-resistant clones and possibly delaying progression to castrate-resistant disease.
Written by:
Bhattasali O1, Chen LN1, Tong M1, Lei S1, Collins BT1, Krishnan P2, Kalhorn C3, Lynch JH4, Suy S1, Dritschilo A1, Dawson NA5, Collins SP1 Are you the author?
Department of Radiation Medicine, Georgetown University Hospital, Washington, DC, USA
Reference: Front Oncol. 2013 Dec 3;3:293
doi: 10.3389/fonc.2013.00293
PubMed Abstract
PMID: 24350058
UroToday.com Prostate Cancer Section
